Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
NCT ID: NCT06567015
Last Updated: 2025-09-17
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
171 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-09-17
Study Completion Date
2030-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this First-In-Human (FIH) Phase I/II trial is to establish the safety profile, determine the Recommended Phase II Dose (RP2D), explore the pharmacokinetic (PK) exposure and pharmacodynamic (PD) properties as well as assess the efficacy of STX-241/PFL-241, a mutant selective Central Nervous System (CNS)-penetrant fourth generation EGFR TKI, in participants with locally advanced or metastatic NSCLC that progressed during or following third generation EGFR TKI such as osimertinib due to C797X double acquired (secondary) mutations.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
NCT06043817
Non-Small Cell Lung Cancer
NSCLC
EGFR/HER2 Exon 20 Insertion Mutation
RECRUITING
PHASE1/PHASE2
A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR
NCT02178397
NSCLC Patients With EGFR Activating Mutation
TERMINATED
PHASE3
Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex
NCT02876081
SMALL CELL LUNG CARCINOMA
WITHDRAWN
PHASE2
Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer
NCT00579683
Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC)
COMPLETED
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
NCT05364073
Non-Small Cell Lung Cancer (NSCLC)
Metastatic Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
+3 more
ACTIVE_NOT_RECRUITING
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Non-small Cell Lung Cancer (NSCLC)
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SEQUENTIAL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
STX-241/PFL-241
Part 1: Dose Escalation and Backfilling components (Phase Ia) Participants will receive oral (PO) STX-241/PFL-241 twice daily (BID) at fixed doses: 10 mg, 20 mg, 40 mg, 80 mg, 120 mg, 180 mg on a continuous dosing schedule
Part 2: Dose Range Optimization (Phase Ib). Participants will receive oral (PO) STX-241/PFL-241 twice daily (BID) at fixed doses selected from Part 1 within the OBD-MTD range for Part 2 on a continuous dosing schedule.
Group Type
EXPERIMENTAL
STX-241
Intervention Type
DRUG
Film-coated tablet
Route of administration: Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
STX-241
Film-coated tablet
Route of administration: Oral
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
PFL-241
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Signed and dated informed consent for participation in the trial obtained according to International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP), and national/local regulations.
2. Male or female ≥ 18 years of age at the time of signing informed consent.
3. Histological confirmation of locally advanced or metastatic, EGFR-mutant (ex19del or L858R mutations) non-small cell lung cancer (NSCLC) Stage IIIB/C or IV (AJCC 8th edition) not eligible for curative intent surgery or chemoradiation.
4. Part 1\&2 Disease progression on a 3rd generation EGFR TKI-based therapy (monotherapy or in combination) received at any prior line of treatment.
5. Tumor mutation profile:
• Part 1 (backfilling component) and Part 2: Presence of C797X and absence of T790M mutations documented locally (as part of clinical practice) on a sample (blood or tissue) collected after progression on treatment with 3rd generation EGFR TKI.
6. Part 1 (Backfilling component), Part 2: At least one measurable target lesion according to RECIST v1.1.
7. Eastern cooperative oncology group (ECOG) performance status 0-1.
8. Adequate organ function as defined below:
* Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L
* Platelets ≥ 75 x 10\^9/L
* Hemoglobin ≥ 90 g/L.
* Serum total bilirubin ≤ 1.5 x ULN or ≤ 3.0 × ULN for participants with documented Gilbert's syndrome.
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 x ULN. If the participant has liver metastases, AST and ALT ≤5 × ULN.
* Estimated glomerular filtration rate (GFR) ≥ 50 mL/min by CKD-EPI equation
9. Adequate cardiac function as defined below:
* Mean QT interval corrected for heart rate according to Fridericia's formula (QTcF) value ≤ 470 msec for women and ≤ 450 msec for men and no history of long QT syndrome or risk factors for torsade de pointe.
* Left ventricular ejection fraction (LVEF) ≥ 50% .
* Systolic blood pressure \< 150 mmHg and diastolic blood pressure \< 100 mmHg
10. Female participants of childbearing potential:
* Negative highly sensitive serum β-HCG test performed within 7 days prior to first dose of STX-241 (C1D1) and a negative urine pregnancy test performed prior to C1D1.
* Agreement to use one highly effective contraceptive method (as defined in protocol and according to local regulations), starting at screening period, throughout the trial and until at least 182 days (i.e. more than 5 estimated STX- 241 half-lives (2 days) plus 6 months (180 days)) after the last dose of STX-241. If the highly effective method of contraception is a hormonal contraceptive method, it must be supplemented by one additional effective (barrier) method of contraception.
* Agreement to not donate eggs (ova, oocytes) for the purpose of assisted reproduction during the trial and for a period of 182 days after the last dose of STX-241.
Note: a female participant of childbearing potential is a woman who is not permanently sterilized or not postmenopausal (postmenopausal is defined as 12 months with no menses without an alternative medical cause).
11. Male participants/partners with female spouse/partners of childbearing potential must agree to take appropriate precautions to avoid fathering a child, i.e.:
* Consistently use a barrier method \[e.g., condom with spermicidal foam / gel / film /cream/suppository\], and his female partner use a highly effective method of contraception as defined in protocol and according to local regulations), starting at screening and continuing throughout the trial period and for 92 days (ie. more than 5 estimated STX-241 half-lives (2 days) plus 3 months (90 days)) after the last dose of STX-241.
* Not donate sperm from Day 1 (first administration of STX-241) until at least 92 days after the last dose of STX-241.
2. Male or female ≥ 18 years of age at the time of signing informed consent.
3. Histological confirmation of locally advanced or metastatic, EGFR-mutant (ex19del or L858R mutations) non-small cell lung cancer (NSCLC) Stage IIIB/C or IV (AJCC 8th edition) not eligible for curative intent surgery or chemoradiation.
4. Part 1\&2 Disease progression on a 3rd generation EGFR TKI-based therapy (monotherapy or in combination) received at any prior line of treatment.
5. Tumor mutation profile:
• Part 1 (backfilling component) and Part 2: Presence of C797X and absence of T790M mutations documented locally (as part of clinical practice) on a sample (blood or tissue) collected after progression on treatment with 3rd generation EGFR TKI.
6. Part 1 (Backfilling component), Part 2: At least one measurable target lesion according to RECIST v1.1.
7. Eastern cooperative oncology group (ECOG) performance status 0-1.
8. Adequate organ function as defined below:
* Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L
* Platelets ≥ 75 x 10\^9/L
* Hemoglobin ≥ 90 g/L.
* Serum total bilirubin ≤ 1.5 x ULN or ≤ 3.0 × ULN for participants with documented Gilbert's syndrome.
* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0 x ULN. If the participant has liver metastases, AST and ALT ≤5 × ULN.
* Estimated glomerular filtration rate (GFR) ≥ 50 mL/min by CKD-EPI equation
9. Adequate cardiac function as defined below:
* Mean QT interval corrected for heart rate according to Fridericia's formula (QTcF) value ≤ 470 msec for women and ≤ 450 msec for men and no history of long QT syndrome or risk factors for torsade de pointe.
* Left ventricular ejection fraction (LVEF) ≥ 50% .
* Systolic blood pressure \< 150 mmHg and diastolic blood pressure \< 100 mmHg
10. Female participants of childbearing potential:
* Negative highly sensitive serum β-HCG test performed within 7 days prior to first dose of STX-241 (C1D1) and a negative urine pregnancy test performed prior to C1D1.
* Agreement to use one highly effective contraceptive method (as defined in protocol and according to local regulations), starting at screening period, throughout the trial and until at least 182 days (i.e. more than 5 estimated STX- 241 half-lives (2 days) plus 6 months (180 days)) after the last dose of STX-241. If the highly effective method of contraception is a hormonal contraceptive method, it must be supplemented by one additional effective (barrier) method of contraception.
* Agreement to not donate eggs (ova, oocytes) for the purpose of assisted reproduction during the trial and for a period of 182 days after the last dose of STX-241.
Note: a female participant of childbearing potential is a woman who is not permanently sterilized or not postmenopausal (postmenopausal is defined as 12 months with no menses without an alternative medical cause).
11. Male participants/partners with female spouse/partners of childbearing potential must agree to take appropriate precautions to avoid fathering a child, i.e.:
* Consistently use a barrier method \[e.g., condom with spermicidal foam / gel / film /cream/suppository\], and his female partner use a highly effective method of contraception as defined in protocol and according to local regulations), starting at screening and continuing throughout the trial period and for 92 days (ie. more than 5 estimated STX-241 half-lives (2 days) plus 3 months (90 days)) after the last dose of STX-241.
* Not donate sperm from Day 1 (first administration of STX-241) until at least 92 days after the last dose of STX-241.
Exclusion Criteria
1. Participant candidate for targeted therapies available to them (such as but not limited to therapies targeting ALK, BRAF, MET, NTRK, ROS1) as identified by local testing performed after progression to the last line of systemic therapy.
2. Participant with rapid progressive disease eligible to receive a platinum-based chemotherapy.
3. Participant unable ingest or digest tablets. This can be caused by any impaired gastrointestinal function or disease, such as for example: ulcerative diseases, malabsorption syndrome, small bowel resection, ileus, etc. or any condition causing uncontrolled nausea, vomiting or diarrhea.
4. History of a primary malignancy other than NSCLC with the exception of:
* Participants with a previous malignancy that completed all anticancer treatment at least 2 years before signing informed consent and with no evidence of residual disease from the prior malignancy at screening.
* Malignancies with a negligible risk of metastasis or death (i.e. 5-year overall survival rate \> 90%) that are adequately treated - Examples include, but are not limited to, completely resected basal cell carcinoma and squamous cell carcinoma of skin, melanoma in situ, curatively treated prostate cancer, breast cancer and early gastric cancer cured by endoscopic mucosal resection or endoscopic submucosal dissection.
5. Spinal cord compression or CNS metastases that are associated with progressive neurological symptoms or require increasing doses of corticosteroids to control the CNS disease. If a participant requires corticosteroids for management of CNS disease, the dose must have been stable for 2 weeks prior to enrollment in the trial.
6. History of hypersensitivity to active or inactive ingredients of STX-241, or drugs with a similar chemical structure or from the same class.
7. Active, bacterial, fungal, or viral infection, including, but not limited to: Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and known Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS)-related illness, tuberculosis or an infection requiring systemic therapeutic treatment within 2 weeks prior to Day 1 (first administration of STX-241).
Note: Participants with known HIV infection are permitted if they have controlled infection (undetectable viral load \[HIV ribonucleic acid polymerase chain reaction (PCR)\] and CD4 count \>350 either spontaneously or on a stable antiviral regimen). For participants with controlled HIV infection, monitoring will be performed per local standards.
8. Positive SARs-CoV-2 or variants of SARs-CoV2 RT-PCR test or suspected to be infected with SARs-CoV2 or variants of SARsCoV2 with confirmation pending within 2 weeks of first dose of STX-241.
9. Impaired cardiovascular function or clinically significant cardiovascular disease (either active or within 6 months prior to signing informed consent), including any of the following:
* Myocardial infarction, acute coronary syndromes including unstable angina, coronary/peripheral artery bypass graft, coronary angioplasty or stenting.
* Symptomatic congestive heart failure (New York Heart Association Classification Class ≥ II).
* Cerebrovascular accident or transient ischemic attack.
* Symptomatic bradycardia, requirement for anti-arrhythmic medication.
* Ongoing cardiac dysrhythmias of NCI-CTCAE Grade ≥2.
10. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection or psychiatric illness/social situation that would limit compliance with trial requirements.
11. Past medical history of Interstitial Lung Disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.
12. Past medical history of Stevens-Jonhson Syndrome (SJS) or Toxic epidermal necrolysis (TEN) or any evidence of clinically active SJS/TEN.
13. Women who are breast feeding.
14. Prior anticancer therapy:
* EGFR-targeted TKI within 7 days prior to the first dose of STX-241.
* Any other systemic anticancer therapy within 28 days or 5 half-lives prior to the first dose of STX-241, whichever is the shortest, but with a minimum of 14 days in all circumstances.
* Radiotherapy to a large field or including a vital organ (including whole brain radiotherapy or stereotactic radiosurgery to brain) within 14 days before the first dose of STX-241.
15. Live attenuated vaccine received within 30 days prior to the first dose of STX-241.
16. Any toxicities from prior therapy with a NCI-CTCAE Grade ≥1 at the time of the first dose of STX-241 (C1D1). Exceptions include alopecia (any grade), fatigue with a Grade ≤2, and peripheral neuropathy with a Grade ≤2.
17. Major surgical procedure within 14 days of the first dose of STX-241 (procedures such as central venous catheter placement, tumor needle biopsy, and feeding tube placement are not considered major surgical procedures). Sequelae of surgical procedures must have resolved, including adequate wound healing, prior to the first dose of STX-241.
18. Treatment with a prohibited medication or herbal remedy known to be strong CYP1A2 or CYP3A4 inducers, strong CYP1A2 or CYP3A4 inhibitors, sensitive CYP1A2, CYP2B6 and CYP3A4 substrates, sensitive MATE1 and OATP1B1 substrates and proton pump inhibitors (PPI) and H2 antagonists unless discontinued prior to the first administration of STX-241 within the following timeframe:
* At least 5 half-lives plus 14 days for strong CYP inducers.
* At least 5 half-lives for CYP inhibitors, CYP/transporter substrates, proton pump inhibitor (PPI) and H2 antagonists.
19. Participation in a clinical trial with administration of an investigational drug within 5 half-lives plus 14 days of the investigational drug, before the first dose of STX-241.
20. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e. g, could compromise the participant's well-being) or would prevent, limit, or confound the protocol-specified assessments.
21. Employee or family member of the investigator or site staff.
2. Participant with rapid progressive disease eligible to receive a platinum-based chemotherapy.
3. Participant unable ingest or digest tablets. This can be caused by any impaired gastrointestinal function or disease, such as for example: ulcerative diseases, malabsorption syndrome, small bowel resection, ileus, etc. or any condition causing uncontrolled nausea, vomiting or diarrhea.
4. History of a primary malignancy other than NSCLC with the exception of:
* Participants with a previous malignancy that completed all anticancer treatment at least 2 years before signing informed consent and with no evidence of residual disease from the prior malignancy at screening.
* Malignancies with a negligible risk of metastasis or death (i.e. 5-year overall survival rate \> 90%) that are adequately treated - Examples include, but are not limited to, completely resected basal cell carcinoma and squamous cell carcinoma of skin, melanoma in situ, curatively treated prostate cancer, breast cancer and early gastric cancer cured by endoscopic mucosal resection or endoscopic submucosal dissection.
5. Spinal cord compression or CNS metastases that are associated with progressive neurological symptoms or require increasing doses of corticosteroids to control the CNS disease. If a participant requires corticosteroids for management of CNS disease, the dose must have been stable for 2 weeks prior to enrollment in the trial.
6. History of hypersensitivity to active or inactive ingredients of STX-241, or drugs with a similar chemical structure or from the same class.
7. Active, bacterial, fungal, or viral infection, including, but not limited to: Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), and known Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS)-related illness, tuberculosis or an infection requiring systemic therapeutic treatment within 2 weeks prior to Day 1 (first administration of STX-241).
Note: Participants with known HIV infection are permitted if they have controlled infection (undetectable viral load \[HIV ribonucleic acid polymerase chain reaction (PCR)\] and CD4 count \>350 either spontaneously or on a stable antiviral regimen). For participants with controlled HIV infection, monitoring will be performed per local standards.
8. Positive SARs-CoV-2 or variants of SARs-CoV2 RT-PCR test or suspected to be infected with SARs-CoV2 or variants of SARsCoV2 with confirmation pending within 2 weeks of first dose of STX-241.
9. Impaired cardiovascular function or clinically significant cardiovascular disease (either active or within 6 months prior to signing informed consent), including any of the following:
* Myocardial infarction, acute coronary syndromes including unstable angina, coronary/peripheral artery bypass graft, coronary angioplasty or stenting.
* Symptomatic congestive heart failure (New York Heart Association Classification Class ≥ II).
* Cerebrovascular accident or transient ischemic attack.
* Symptomatic bradycardia, requirement for anti-arrhythmic medication.
* Ongoing cardiac dysrhythmias of NCI-CTCAE Grade ≥2.
10. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection or psychiatric illness/social situation that would limit compliance with trial requirements.
11. Past medical history of Interstitial Lung Disease (ILD), drug-induced ILD, radiation pneumonitis that required steroid treatment, or any evidence of clinically active ILD.
12. Past medical history of Stevens-Jonhson Syndrome (SJS) or Toxic epidermal necrolysis (TEN) or any evidence of clinically active SJS/TEN.
13. Women who are breast feeding.
14. Prior anticancer therapy:
* EGFR-targeted TKI within 7 days prior to the first dose of STX-241.
* Any other systemic anticancer therapy within 28 days or 5 half-lives prior to the first dose of STX-241, whichever is the shortest, but with a minimum of 14 days in all circumstances.
* Radiotherapy to a large field or including a vital organ (including whole brain radiotherapy or stereotactic radiosurgery to brain) within 14 days before the first dose of STX-241.
15. Live attenuated vaccine received within 30 days prior to the first dose of STX-241.
16. Any toxicities from prior therapy with a NCI-CTCAE Grade ≥1 at the time of the first dose of STX-241 (C1D1). Exceptions include alopecia (any grade), fatigue with a Grade ≤2, and peripheral neuropathy with a Grade ≤2.
17. Major surgical procedure within 14 days of the first dose of STX-241 (procedures such as central venous catheter placement, tumor needle biopsy, and feeding tube placement are not considered major surgical procedures). Sequelae of surgical procedures must have resolved, including adequate wound healing, prior to the first dose of STX-241.
18. Treatment with a prohibited medication or herbal remedy known to be strong CYP1A2 or CYP3A4 inducers, strong CYP1A2 or CYP3A4 inhibitors, sensitive CYP1A2, CYP2B6 and CYP3A4 substrates, sensitive MATE1 and OATP1B1 substrates and proton pump inhibitors (PPI) and H2 antagonists unless discontinued prior to the first administration of STX-241 within the following timeframe:
* At least 5 half-lives plus 14 days for strong CYP inducers.
* At least 5 half-lives for CYP inhibitors, CYP/transporter substrates, proton pump inhibitor (PPI) and H2 antagonists.
19. Participation in a clinical trial with administration of an investigational drug within 5 half-lives plus 14 days of the investigational drug, before the first dose of STX-241.
20. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e. g, could compromise the participant's well-being) or would prevent, limit, or confound the protocol-specified assessments.
21. Employee or family member of the investigator or site staff.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pierre Fabre Medicament
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium)
Nashville, Tennessee, United States
Site Status
RECRUITING
Oncology Consultants (OC) - Texas Medical Center - Cancer Center
Houston, Texas, United States
Site Status
RECRUITING
Shanghai East Hospital, Tongji University
Shanghai, , China
Site Status
RECRUITING
Tianjin Medical University Cancer Institute and Hospital
Tianjin, , China
Site Status
RECRUITING
Centre Léon Bérard
Lyon, , France
Site Status
RECRUITING
CHU Hôpital de la Timone
Marseille, , France
Site Status
RECRUITING
Institut de Cancérologie de l'Ouest (ICO) - René Gauducheau
Saint-Herblain, , France
Site Status
RECRUITING
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, , France
Site Status
RECRUITING
Gustave Roussy
Villejuif, , France
Site Status
RECRUITING
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, , Germany
Site Status
RECRUITING
Netherlands Cancer Institute
Amsterdam, , Netherlands
Site Status
RECRUITING
Vall d'Hebron Institut d'Oncologia
Barcelona, , Spain
Site Status
RECRUITING
Hospital Universitario La Paz
Madrid, , Spain
Site Status
RECRUITING
Centro Integral Oncológico Clara Campal (CIOCC)
Madrid, , Spain
Site Status
RECRUITING
National Taiwan University Hospital
Taipei, , Taiwan
Site Status
RECRUITING
Taipei Veterans General Hospital
Taipei, , Taiwan
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
China
France
Germany
Netherlands
Spain
Taiwan
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
https://clinicaltrials.pierre-fabre.com/en/our-commitments
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Pierre Fabre's commitment to transparency of clinical study information Pillar 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-510203-21-00
Identifier Type: CTIS
Identifier Source: secondary_id
F60087CI101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
NCT02088112
COMPLETED
PHASE1
A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody
NCT06048315
NOT_YET_RECRUITING
PHASE3
Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR
NCT01556191
COMPLETED
PHASE2
Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)
NCT02575560
COMPLETED
D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer
NCT03861156
COMPLETED
PHASE2
Combination of Chemotherapy and Gefitinib as First-line Treatment
NCT02148380
COMPLETED
NA
A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies
NCT02108964
COMPLETED
PHASE1/PHASE2
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
NCT05900219
UNKNOWN
PHASE2
A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities
NCT07308106
NOT_YET_RECRUITING
PHASE2
Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC
NCT02064491
COMPLETED
PHASE2
First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer
NCT06521034
COMPLETED
PHASE1/PHASE2
Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC
NCT01755923
UNKNOWN
PHASE2
Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation
NCT05519293
RECRUITING
PHASE1/PHASE2
Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients
NCT01588145
COMPLETED
PHASE1/PHASE2
First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
NCT00344773
COMPLETED
PHASE2
Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations
NCT01470716
UNKNOWN
PHASE2
Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy
NCT01746277
UNKNOWN
PHASE2
Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
NCT04768491
UNKNOWN
Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations
NCT04811001
UNKNOWN
PHASE2
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
NCT06046495
RECRUITING
PHASE1
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
NCT01230710
COMPLETED
PHASE4
A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
NCT06110663
UNKNOWN
PHASE3
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
NCT06668103
RECRUITING
PHASE2
Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
NCT04207775
COMPLETED
Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer
NCT03461185
UNKNOWN
PHASE2